Human Microbiome Sequencing Market to Register Exponential CAGR by 2030 – InsightAce Analytic Exclusive Report

Global Human Microbiome Sequencing Market Insights

Global Human Microbiome Sequencing Market Segmentation

Global Human Microbiome Sequencing Market Segmentation

The global human microbiome sequencing market is estimated to exhibit a CAGR of 20.31% during the forecast period.

Leading Players in Human Microbiome Sequencing Market: Baseclear BV, Beijing Genomics Institute (BGI) Genomics Co, Ltd, Charles River Laboratories International Inc., Clinical Microbiomics”

— Insightace analysis

NEW JERSEY, NJ, USA, Oct. 3, 2022 /EINPresswire.com/ — InsightAce Analytic Pvt. announces the publication of a Market Assessment Report on the “Global Human Microbiome Sequencing Market by (Product Type (Kits and Assays, Instruments and Software), Technology (Sequencing by Synthesis, Sequencing by Ligation and Other next-generation sequencing), Traditional sequencing technologies (pyrosequencing and Sanger sequencing) and other sequencing technologies Application (diagnosis of diseases (gastrointestinal diseases, metabolic diseases, oncology, infectious diseases, neurological diseases and other diseases), discovery of drugs, consumer welfare, omics analysis (genome analysis, metabolome analysis, transcriptome analysis and other omics analysis) and other applications), end user (research and academic institutions, pharmaceutical and biotechnology companies and other end users) – Trends, industry competition analysis, revenue and pr revisions until 2030.”

The global human microbiome sequencing market is estimated to exhibit a CAGR of 20.31% during the forecast period.

Request a sample: https://www.insightaceanalytic.com/request-sample/1380

The term “human microbiome” refers to the assortment of microorganisms that reside on and within the human body. Many organisms make up the human microbiome, including bacteria, bacteriophages, fungi, protozoa, and viruses. Microbial cells constitute ten times more human cells than human cells. The human body contains so many of these microorganisms that they weigh about 2-3 kg. The human microbiome sequencing market is expanding due to the increased use of microbiomes in genomics, proteomics, and metabolomics, as well as developments in next-generation sequencing (NGS) technology. The market is growing due to the increased focus on human microbiome therapy as a new established target for therapeutic development. Additionally, the market for human microbiome sequencing is growing due to the increased use of microbiome for early detection and diagnosis of diseases and decreasing sequencing costs. The demand for human microbiome sequencing is expected to increase due to increasing collaborations, research expenditures, and the need for investigational new drugs (INDs) for the fecal microbiota. The expansion of genomic research globally is fueling the predicted growth of the human microbiome sequencing market. The market for human microbiome sequencing is booming thanks to numerous research and development efforts in genomics.

List of Major Players of Human Microbiome Sequencing Market:
• Baseclear B.V.
• Beijing Genomics Institute (BGI) Genomics Co., Ltd.
• Charles River International Laboratories Inc.
• Clinical Microbiology A/S
• Eurofins Scientific SE
• GENEWIZ, Inc.
• Illumina, Inc.
• Novogen Corporation
• OraSure Technologies, Inc.
• Oxford Nanopore Technologies, Inc.
• Pacific Biosciences of California, Inc.
• QIAGEN SA
• Second Genome, Inc.
• Thermo Fisher Scientific Inc.
• Viome, Inc.
• Cosmos ID
• Leucine Rich Bio Pvt. ltd.
• Microbe
• Microbiome Insights Inc.
• Molzym GmbH & Co. KG

Market dynamics:
Drivers-
The human intestinal flora significantly improves the effectiveness of pharmaceuticals. Studies have shown that the right microbial balance in the human body helps in treating various diseases. This link between particular disease states and bacteria may present new insights for drug development (or vaccine makers). Microbes are abundant suppliers of enzymes, which makes them useful for various therapeutic purposes, including the search for innovative treatments. With several small, innovative players operating in the market, there are many high-growth opportunities for critical stakeholders to acquire companies so that microbiomes can be studied in hopes of discovering new drugs and drug targets for a variety of indications including obesity, liver disorders, diabetes and metabolic disorders. Strategic alliances and collaborations are a top priority for many market leaders as they strive to expand their product pipelines through effective research and development methods.

Challenges:
Probiotics have not received FDA approval as a live biotherapeutic product (a biological product, other than a vaccine, that includes living organisms and is used to treat or prevent human disease.). Foods containing FDA-regulated probiotics, including dietary supplements, are nonetheless marketed legally even though they cannot be used to treat, prevent, or alleviate disease. The FDA is considering changing its description of probiotics. There may be a distinct or entirely new set of regulatory hurdles for genetically modified microorganisms. Additionally, parallel control groups of healthy individuals must be compared for the present methods of identifying microbial indicators for diagnostic purposes to be effective. It can be difficult to determine which microbe is best suited for a certain application, making it difficult to choose the appropriate microbial chassis for microbiota-based therapy.

Regional trends:
North America currently holds a dominant position in the human microbiome sequencing market owing to the region’s robust healthcare infrastructure, increasing investments by large companies in the development of cutting-edge devices, drug development and research activities. The dominance of the region is also tied to improvements in next-generation sequencing and the growing prevalence of lifestyle issues. For example, a leading US company, Illumina Inc., claims that the development of next-generation sequencing has made several high-level collaborative projects possible, such as the Human Microbiome Project and MetaHIT. These initiatives have used next-generation sequencing as the main instrument to publish a wide range of data on the human microbiome. Asia-Pacific is expected to grow over the projection period as more institutions open up in related sectors and the microbiome. Rising prevalence of lifestyle-related diseases, increased awareness of preventive health care, funding for microbiome research, and growing number of microbiome research and clinical activities are propelling the growth of the regional market.

Key developments: https://www.insightaceanalytic.com/enquiry-before-buying/1380

RECENT DEVELOPMENTS:
• In September 2021, PhenoBiome announced that its first human gut microbiome test would be available through Genetic Direction, a Dallas-based distributor of genetics-based health management solutions. Clinical Enterprise, Inc., a subsidiary of Eurofins Scientific, will perform the testing in its CLIA and CAP certified laboratory.
• In July 2021, Seres Therapeutics Inc. and Nestlé Health Science agreed to collaborate on the commercialization of SER-109, an investigational oral microbiome treatment for recurrent Clostridioides difficile infection (CDI), in the United States (US). -U.) and Canada. If approved, SER-109 will be the first FDA-approved microbiome treatment.

Human Microbiome Sequencing Market Segmentation-
By product type
• Kits and assays
• Instruments
• Software
By technology
• Next Generation Sequencing
o Sequencing by synthesis
o Sequencing by Ligature
o Other next-generation sequencing technologies
• Traditional sequencing technologies
o Pyrosequencing
o Sanger sequencing
• Other sequencing technology
By app
• Diagnoses of diseases
o Gastrointestinal diseases
o Metabolic diseases
o Oncology
o Infectious diseases
o Neurological diseases
o Other illnesses
• Drug discovery
• Consumer well-being
• Omic analysis
o Genome analysis
o Metabolome analysis
o Transcriptome analysis
o Other omics analyzes
• Other app
Per end user
• Research and academic institutions
• Pharmaceutical and biotechnology companies
• Other end users
By region-
• North America-
o United States
o Canada
o Mexico
• Europe-
o Germany
o United Kingdom
o France
o Italy
o Spain
o Rest of Europe
• Asia Pacific-
o China
o Japan
o India
o South Korea
o Southeast Asia
o Rest of Asia-Pacific
• Latin America-
o Brazil
o Argentina
o Rest of Latin America
• Middle East and Africa-
o GCC countries
o South Africa
o Rest of the Middle East and Africa

For information: https://www.insightaceanalytic.com/customisation/1380

Priyanka Tilekar
Insightace Analytical Pvt. ltd.
+1 551-226-6109
write to us here

Comments are closed.